Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer

Summary

This randomized phase II trial studies how well ziv-aflibercept (VEGF Trap) works in treating patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) or is unable to be removed with surgery (unresectable). Ziv-aflibercept may stop the growth of kidney cancer by blocking blood flow to the tumor.

Timeline

Start

2007-12

Primary completion

2015-10

Completion

2015-10

Drugs

Indications